In this respect, since few therapeutic options are available for wt EGFR/Ras mutant NSCLC, the combination of dasatinib plus selumetinib may be a novel, potentially valuable strategy in the clinical setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.